Meet and network with the key influencers shaping the law, policy and proceedings of Paragraph IV litigation.
Each spring, leading pharmaceutical patent litigators for brand name and generic drug companies gather at the Paragraph IV Disputes conference to discuss, debate, and analyze the latest trends, judicial rulings and legislative developments affecting Hatch-Waxman litigation.
As the industry prepares to address the fall out of global pharmaceutical patent losses of billions of dollars on the Hatch-Waxman landscape, the time for this conference has never been more relevant.
Get judicial insights on the complex challenges facing both brand name and generic drug manufacturers:
United States District Court
District of Delaware
Honorable
Leonard P. Stark
Chief Judge
Honorable
Mary Pat Thynge
Chief Magistrate Judge
Honorable
Christopher J. Burke
Magistrate Judge
District of New Jersey
Eastern District of Texas
Honorable
Jose L. Linares
Chief Judge
Honorable
Tonianne J. Bongiovanni
Magistrate Judge
Honorable
Roy Payne
Magistrate Judge
Hear from the FTC and the FDA on the latest antitrust and regulatory developments impacting Paragraph IV litigation
Markus H. Meier
Assistant Director, Health Care Division,
Bureau of Competition
Federal Trade Commission
Maryll W. Toufanian, J.D.
Acting Director, Office of Generic Drug Policy
Office of Generic Drugs, CDER U.S. Food and Drug Administration
New Features for 2018 conference include:
1
A U.S. DISTRICT COURT JUDGES’ ROUNDTABLE with the Chief Judges from Delaware, The Northern District of Illinois and New Jersey
Do not miss your opportunity to hear directly from
Chief Judges Castillo, Linares, and Stark
2
TC HEARTLAND THINK TANK
Top litigators and leading in house counsel will brainstorm with you on venue and jurisdictional strategies in the aftermath of TC Heartland
3
FOCUS GROUP ON OIL STATES AND SAS
You will have the opportunity to hear from those “in the know” as well as join the discussion on these two pivotal pending Supreme Court decisions and their possible consequences on the future of IPRs
4
FTC KEYNOTE
Markus Meier will provide insights on the latest anti-trust developments affecting Paragraph IV litigation
5
TWO NEW CONFERENCE TRACKS that will contemplate:
The Business of Pharmaceutical Patent Litigation; and
The Practice of Pharmaceutical Patent Litigation
Join our mailing list to stay up-to-date with new announcement on speakers and agenda.
Register now and be part of the prestigious meeting of the minds.
@ACI_Pharma
ACI’s Hatch-Waxman Series
